Clinical spectrum of hepatitis C-related liver disease and response to treatment with interferon and ribavirin in haemophilia or von Willebrand disease
(2001) In British Journal of Haematology 113(1). p.87-93- Abstract
- Our aim was to evaluate the severity of liver disease resulting from chronic hepatitis C in haemophilia or von Willebrand disease and the efficacy of 6 months treatment with interferon alpha and ribavirin. Fifty-five liver biopsies were performed in 43 patients without any bleeding complications, as seen with ultrasound immediately after the biopsy and 48 h thereafter. Histological changes were mild, with low scores for both inflammation and fibrosis, in spite of long exposure to blood products (mean 27 years). Two patients had compensated cirrhosis. Thirty-five out of 39 included patients completed study treatment. Hepatitis C virus (HCV)-RNA was negative in 77% (30/39) of patients at the end of treatment, and 36% (14/39) achieved a... (More)
- Our aim was to evaluate the severity of liver disease resulting from chronic hepatitis C in haemophilia or von Willebrand disease and the efficacy of 6 months treatment with interferon alpha and ribavirin. Fifty-five liver biopsies were performed in 43 patients without any bleeding complications, as seen with ultrasound immediately after the biopsy and 48 h thereafter. Histological changes were mild, with low scores for both inflammation and fibrosis, in spite of long exposure to blood products (mean 27 years). Two patients had compensated cirrhosis. Thirty-five out of 39 included patients completed study treatment. Hepatitis C virus (HCV)-RNA was negative in 77% (30/39) of patients at the end of treatment, and 36% (14/39) achieved a complete sustained response at follow-up 6 months after treatment. Treatment failure was more frequent in patients with virus genotype 1 compared with non-1 (P = 0.0003). The response rate correlated well with that of non-haemophilic patients. In summary: (1) liver biopsy was safe with our regimen; (2) liver disease in our patients was usually mild and had a slow progress; (3) only HCV genotype 1 predicted treatment failure; (4) our treatment results agreed with those from non-haemophilic patients. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1120035
- author
- Lethagen, Stefan LU ; Widell, Anders LU ; Berntorp, Erik LU ; Verbaan, Hans LU and Lindgren, Stefan LU
- organization
- publishing date
- 2001
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- hepatitis C, haemophilia, von Willebrand disease, interferon, ribavirin
- in
- British Journal of Haematology
- volume
- 113
- issue
- 1
- pages
- 87 - 93
- publisher
- Wiley-Blackwell
- external identifiers
-
- pmid:11328286
- scopus:0035001973
- ISSN
- 0007-1048
- DOI
- 10.1046/j.1365-2141.2001.02700.x
- language
- English
- LU publication?
- yes
- id
- 8d40c258-b49e-4cf8-b0ef-27007d2c6edd (old id 1120035)
- date added to LUP
- 2016-04-01 11:53:26
- date last changed
- 2022-04-20 23:19:54
@article{8d40c258-b49e-4cf8-b0ef-27007d2c6edd,
abstract = {{Our aim was to evaluate the severity of liver disease resulting from chronic hepatitis C in haemophilia or von Willebrand disease and the efficacy of 6 months treatment with interferon alpha and ribavirin. Fifty-five liver biopsies were performed in 43 patients without any bleeding complications, as seen with ultrasound immediately after the biopsy and 48 h thereafter. Histological changes were mild, with low scores for both inflammation and fibrosis, in spite of long exposure to blood products (mean 27 years). Two patients had compensated cirrhosis. Thirty-five out of 39 included patients completed study treatment. Hepatitis C virus (HCV)-RNA was negative in 77% (30/39) of patients at the end of treatment, and 36% (14/39) achieved a complete sustained response at follow-up 6 months after treatment. Treatment failure was more frequent in patients with virus genotype 1 compared with non-1 (P = 0.0003). The response rate correlated well with that of non-haemophilic patients. In summary: (1) liver biopsy was safe with our regimen; (2) liver disease in our patients was usually mild and had a slow progress; (3) only HCV genotype 1 predicted treatment failure; (4) our treatment results agreed with those from non-haemophilic patients.}},
author = {{Lethagen, Stefan and Widell, Anders and Berntorp, Erik and Verbaan, Hans and Lindgren, Stefan}},
issn = {{0007-1048}},
keywords = {{hepatitis C; haemophilia; von Willebrand disease; interferon; ribavirin}},
language = {{eng}},
number = {{1}},
pages = {{87--93}},
publisher = {{Wiley-Blackwell}},
series = {{British Journal of Haematology}},
title = {{Clinical spectrum of hepatitis C-related liver disease and response to treatment with interferon and ribavirin in haemophilia or von Willebrand disease}},
url = {{http://dx.doi.org/10.1046/j.1365-2141.2001.02700.x}},
doi = {{10.1046/j.1365-2141.2001.02700.x}},
volume = {{113}},
year = {{2001}},
}